Budget Amount *help |
¥16,510,000 (Direct Cost: ¥12,700,000、Indirect Cost: ¥3,810,000)
Fiscal Year 2021: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
Fiscal Year 2020: ¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
Fiscal Year 2019: ¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
Fiscal Year 2018: ¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2017: ¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
|
Outline of Final Research Achievements |
Various antioxidant drugs have been clinically applied to reduce oxidative stress, but none have achieved sufficient therapeutic efficacy. Selenoprotein P (SeP) is a hepatokine, a bioactive molecule derived from the liver, which plays roles in the pathogenesis of type 2 diabetes. In the present study, we show that SeP is an endogenous factor that induces signal transduction via eliminating physiological reactive oxygen species. Such SeP-mediated reductive stress caused diabetic pathology in the brown adipose tissue and bone. These findings suggest that SeP is a potential novel therapeutic target against diabetic complications.
|